R&D Systems Human IL-18 R beta/IL-1 R7 Fc Chimera Recombinant Protein
Manufacturer: R&D Systems 118AP100
DescriptionMeasured by its ability to inhibit the IL-18-induced response of KG-1 human acute myelogenous leukemia cells in the presence of soluble Recombinant Human IL-18 R alpha/IL-1 R5 Fc Chimera (Catalog # 816-LR ). The ED 50 for this effect is 2-6 µg/mL in the presence of 30 µg/mL of soluble IL-18 R alpha/Fc Chimera and 40 ng/mL of human IL-18.
|Lyophilized from a 0.2μm filtered solution in PBS.|
|65.1 kDa (monomer)|
|90%, by SDS-PAGE under reducing conditions and visualized by silver stain.|
|IL-18 R beta/IL-1 R7 Fc Chimera|
|Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70° C as supplied. 1 month, 2 to 8° C under sterile conditions after reconstitution. 3 months, -20 to -70° C under sterile conditions after reconstitution.|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok